Individualizing Interventions for Cancer Prevention
Many cancer prevention strategies are unlikely to provide equal risk reduction in all subjects, but instead are predicted to be particularly useful for specific individuals. An important research challenge is to devise methods for individualization of cancer prevention recommendations, such that particular interventions are assigned to those who will gain the most. Research in this area is at an early stage, but progress that allows rational assignment of specific prevention strategies to particular individuals who will benefit would decrease the cost, minimize the toxicity, and increase the efficacy of interventions intended to prevent cancer.
KeywordsBreast Cancer Risk Cancer Prevention BRCA1 Mutation Natl Cancer Inst Sporadic Breast Cancer
Unable to display preview. Download preview PDF.
- 2.Fisher B, Costantino JP, Wickerham DL, Redmond CK, Daly M, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
- 3.King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedGoogle Scholar
- 4.Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P, Tamoxifen Study Group (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165PubMedGoogle Scholar
- 16.Costantino JP (2001) Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. Ann N YAcad Sci 949: 280–285Google Scholar
- 17.Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ (1997) Circulating and skeletal insulin-like growth factor-I (IGF-1) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21: 217–223PubMedCrossRefGoogle Scholar